Overview
DYN market data
Price History
DYN price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$3.47 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.11 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $10.78 – $27.13 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $4.9B · P/B 3.26.
Company News
Morgan Stanley Maintains Overweight on Dyne Therapeutics, Lowers Price Target to $45Benzinga · Jul 31, 2026, 5:31 PM
RBC Capital Maintains Outperform on Dyne Therapeutics, Raises Price Target to $35Benzinga · Jul 30, 2026, 5:42 PM
Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) EstimateBenzinga · Jul 29, 2026, 9:32 PM
8-K filing — Dyne Therapeutics, Inc. (DYN)SEC EDGAR · Jul 29, 2026, 8:35 PM
Dyne Therapeutics Announces FDA Clearance Of IND Application For DYNE-302, Enabling Phase 1 Trial In FSHDBenzinga · Jul 28, 2026, 11:35 AM
Cantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight RatingBenzinga · Jul 23, 2026, 1:49 PM
Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market SessionBenzinga · Jul 22, 2026, 1:19 PM
Dyne Therapeutics shares are trading lower after the company announced the pricing of its $376 million offering of 18.3 million shares at $20.50 per share.Benzinga · Jul 22, 2026, 11:55 AM
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common StockGlobenewswire Inc · Jul 22, 2026, 11:00 AM
Reported Earlier, Dyne Therapeutics Prices Upsized $375M Public Offering Of 18.3M Common Shares At $20.50 Per ShareBenzinga · Jul 22, 2026, 6:22 AM